Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Interviews Jeffrey Gottfurcht, World's First Climber with Rheumatoid Arthritis to Attempt to Scale Mount Everest
March 09, 2011

Nutra Pharma Interviews Jeffrey Gottfurcht,

World’s First Climber with Rheumatoid Arthritis to Attempt to Scale Mount Everest

 

Nutra Pharma recently interviewed Jeffrey Gottfurcht, founder of the Jeffrey Gottfurcht Children’s Arthritis Foundation, about his upcoming Mount Everest expedition and the physical challenges he faces as a sufferer of Rheumatoid Arthritis.

 

March 9, 2011 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, published an in-depth interview with Jeffrey Gottfurcht, founder of the Jeffrey Gottfurcht Children’s Arthritis Foundation (JGCAF). He is the first climber in the world with Rheumatoid Arthritis (RA) to attempt to scale Mount Everest. In January of this year, Nutra Pharma announced its sponsorship of Jeffrey Gottfurcht’s quest to climb the world’s tallest mountain.

 

Gottfurcht, who lives in the San Francisco area, will begin his expedition in late March, 2011 to climb the 29,035-foot Everest. He will be accompanied by an expert guide and a Sherpa on what is typically a six-week climb, subject to favorable weather conditions. Gottfurcht confessed, “I’ve actually been somewhat obsessed with climbing Mount Everest ever since I was a child.” This Mount Everest climb serves to not only meet a personal goal but also to raise the awareness of Rheumatoid Arthritis.

 

At 28 Jeffrey Gottfurcht was diagnosed with Rheumatoid Arthritis, an autoimmune disease that attacks the joints and causes inflammation, joint pain and stiffness. Patients with severe cases may have deformed hands, wrists or feet and can be bound to a wheel chair.  Jeff’s disease inspired him to found the Jeffrey Gottfurcht Children’s Arthritis Foundation (JGCAF), an organization that grants dreams for juvenile arthritis patients.

 

Gottfurcht is not new to climbing, as he has successfully scaled other mountains since his teen years. In preparation to climb Everest, Gottfurcht spends five days per week training alone. “I switch off between hiking for 12 miles with 50 lbs on my back and running at different speeds. Interval training is the best way to get fit and keep your heart rate high. Plus I practice yoga and meditation for 30 minutes,” he explains. “You must have the mindset to endure the physical pain and suffering you will encounter and also be able to handle, emotionally, the time away from your family.”

 

To control his pain from RA, Gottfurcht has been using Nyloxin™ since the middle of last summer. It has been so effective in easing his pain that it is currently the only drug he is taking for his Rheumatoid Arthritis. “Nyloxin has already proven to truly be a remarkable part of my mountain climbing mission, and I can’t imagine climbing Everest without it,” Gottfurcht said. Nyloxin is currently available in the United States as an over the counter, non-addictive oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. It is available in every-day strength as well as in an extra strength formula for more advanced chronic pain. 

 

“Through his organization and his quest to scale Everest, Jeff Gottfurcht has already been an inspiration to those challenged with Rheumatoid Arthritis and we join his efforts to build awareness of this debilitating disease,” noted Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We were confident that Nyloxin would be beneficial in helping Jeff manage his chronic pain. Now it is our hope at Nutra Pharma that the many other chronic pain sufferers out there discover the benefits of Nyloxin as an alternative to potentially dangerous OTC and prescription pain medications,” Deitsch added.

 

“Not one person has tried to talk me out of this climb,” Gottfurcht proudly declared. As far as advice to others living with chronic pain he said, “There are no borders, no limits and no frontier. Just keep moving, and do exactly what you set out to do.”

 

To read the entire interview with Jeffrey Gottfurcht, visit the Nutra Pharma blog at: http://tinyurl.com/mounteverest.

 

About JGCAF

The Jeffrey Gottfurcht Children’s Arthritis Foundation was founded by Jeffrey Gottfurcht as a way to inspire, educate and generate awareness of both rheumatoid and juvenile idiopathic arthritis, as those suffering optimistically await a cure. In 2002, at the age of 28, Gottfurcht was diagnosed with RA and after undergoing years of treatment; he wanted to share his determination to fight the disease while bringing joy, strength and support to children and young adults similarly afflicted. A wish-granting Foundation, JGCAF accepts referrals for dreams from parents, guardians, siblings, members of the medical community, and directly from children suffering from juvenile rheumatoid arthritis. The Foundation’s Dream Team helps select dreams that are prudent and possible and assists in making them come true. Help us fulfill a dream of a child living with Juvenile Arthritis today. For more information please call 310.855.3745 or visit www.JGCAF.org.

 

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

 

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Company's sponsorship of Jeffrey Gottfurcht should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
May 23, 2017
Nutra Pharma Announces Collaboration with the International Security Group for Development of Nerve Agent Counter Measures


March 14, 2017
Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com


February 22, 2017
Global Small Caps Initiates Coverage on Nutra Pharma


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics